Literature DB >> 29566583

Benefits of upgrading to the Nucleus® 6 sound processor for a wider clinical population.

Michelle J Todorov1, Karyn L Galvin1.   

Abstract

OBJECTIVES: To determine whether a large clinical group of cochlear implant (CI) recipients demonstrated a difference in sentence recognition in noise when using their pre-upgrade sound processor compared to when using the Nucleus 6 processor, and to examine the impact of the following factors: implant type, sound processor type, age, or onset of hearing loss.
METHODS: A file review of 154 CI recipients (aged 7-92 years old) who requested an upgrade to the Nucleus 6 sound processor at the Cochlear Care Centre Melbourne was conducted. 105 recipients had complete data collected according to the protocol. A repeated measures, single subject design was used. Performance of CI recipients was compared with their pre-upgrade sound processor versus the Nucleus 6 processor using the Australian Sentence Test in Noise.
RESULTS: Group performance of CI recipients improved by 4.7 dB with the Nucleus 6 compared with the pre-upgrade sound processor. The benefit was not affected by pre-upgrade sound processor type or implant type (including older implant types and sound processors), age or onset of hearing loss (pre-lingual versus post-lingual).
CONCLUSION: This study confirmed that a clinical group of CI recipients obtained a significant benefit when upgrading to the Nucleus 6 sound processor.

Entities:  

Keywords:  Age; Cochlear implant; Cochlear limited; Implant; Nucleus 6; Pre-lingual; Sound processor; speech recognition

Mesh:

Year:  2018        PMID: 29566583     DOI: 10.1080/14670100.2018.1452584

Source DB:  PubMed          Journal:  Cochlear Implants Int        ISSN: 1467-0100


  1 in total

1.  The COVID-19 pandemic and upgrades of CI speech processors for children: part II-hearing outcomes.

Authors:  Anita Obrycka; Artur Lorens; Adam Walkowiak; Elzbieta Wlodarczyk; Beata Dziendziel; Piotr Henryk Skarzynski; Henryk Skarzynski
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-03-14       Impact factor: 3.236

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.